Cancer reports and reviews最新文献_第6页

Comparison of the antineoplastic action of 3-deazaneplanocin-A and inhibitors that target the catalytic site of EZH2 histone methyltransferase 3-deazaneplanocin-A与靶向EZH2组蛋白甲基转移酶催化位点抑制剂抗肿瘤作用的比较

Cancer reports and reviews Pub Date : 2019-01-01 DOI: 10.15761/crr.1000194

Momparler Rl, Côté S, Marquez Ve, Fisher Lf

{"title":"Comparison of the antineoplastic action of 3-deazaneplanocin-A and inhibitors that target the catalytic site of EZH2 histone methyltransferase","authors":"Momparler Rl, Côté S, Marquez Ve, Fisher Lf","doi":"10.15761/crr.1000194","DOIUrl":"https://doi.org/10.15761/crr.1000194","url":null,"abstract":"EZH2 is the histone methyltransferase (HMT) that catalyzes the trimethylation of histone H3 lysine 27 (H3K27me3), a histone marker that silences gene expression. Overexpression of EZH2 enhances the growth of malignant cells due to silencing of tumor suppressor genes (TSGs). 3-deazaneplanocin-A (DZNep) blocks the metabolism of methionine resulting in global inhibition of HMTs, including EZH2. This action of DZNep leads to inhibition of growth of malignant cells and reactivation of TSGs. On the other hand, specific inhibitors that target the catalytic site of EZH2: GSK-126, GSK-343, CPI-1205, and tazemetostat (EPZ-6438) were also investigated and exhibited interesting antineoplastic activity. These studies indicated that their anticancer action required a longer duration of treatment than DZNep to exhibit significant antineoplastic activity. This observation suggests that DZNep is a more potent antineoplastic agent than the specific EZH2 inhibitors. Such a difference in anticancer potency may be explained in part by the limited penetration into cells of the specific EZH2 inhibitors due to their large complex molecular structure as compared to the smaller molecular size of DZNep. An additional explanation is that DZNep has several targets in the cell which contribute to its anticancer action: deregulation of methionine metabolism, proteosomal degradation of EZH2, and activation of miRNAs with TSG function. In this study, we compared the in vitro antineoplastic action of DZNep and the specific EZH2 inhibitors using growth inhibition and colony assays on leukemic cells. These assays confirm that DZNep is a more potent anticancer agent than the specific EZH2 inhibitors. DZNep merits clinical investigation in patients with cancer.","PeriodicalId":91850,"journal":{"name":"Cancer reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67452866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Long-term disease free survival [DFS] of stage IIIB malignant melanoma patient treated post-surgery with herbal treatment modalities IIIB期恶性黑色素瘤患者术后中草药治疗的长期无病生存期

Cancer reports and reviews Pub Date : 2019-01-01 DOI: 10.15761/crr.1000181

S. Sardeshmukh, S. Gangal, Arvind V. Kulkarni, Vineeta Deshmukh, S. Gujar, S. Gore, R. Gayal

{"title":"Long-term disease free survival [DFS] of stage IIIB malignant melanoma patient treated post-surgery with herbal treatment modalities","authors":"S. Sardeshmukh, S. Gangal, Arvind V. Kulkarni, Vineeta Deshmukh, S. Gujar, S. Gore, R. Gayal","doi":"10.15761/crr.1000181","DOIUrl":"https://doi.org/10.15761/crr.1000181","url":null,"abstract":"Objective: Long term survival of high-risk malignant melanoma is difficult to achieve in spite of radical surgery, adjunct chemotherapy, radiotherapy and biological therapy. The aim of this case presentation is to demonstrate effectiveness of herbal combination in achieving long term DFS of a high-risk melanoma patient. Case presentation: We reports here a case of a patient with Stage IIIB malignant melanoma with palpable axillary lymph node. After surgical removal of only the primary lesion he did not opt for radiotherapy or chemotherapy or interferon therapy. Instead, he opted to take combination of herbal medicines at ICTRC, Pune. After the initial period of Ayurvedic treatment for 5 months, the palpable axillary lymph node enlarged. It was subjected to second surgery. The histopathological report of partial second surgery revealed residual melanoma with extensive exudate consisting of lymphocytes and histiocytes indicative of intense immune reactivity. No further recurrence or metastasis is noted for 20 yrs. The patient is continued to take herbal medicines and detoxifying Ayurvedic treatment modality called Panchakarma and is in Disease Free State with good quality of life and fit physical condition. Conclusion: In this case improvement in immune status and quality of life is achieved using herbal medicines and Panchakarma treatment in absence of known anti-cancer treatments. Further clinical studies on large cohort and at the level of basic research are warranted. *Correspondence to: Vineeta Deshmukh, Integrated Cancer Treatment and Research Centre, Wagholi, Pune – 412207, Maharashtra, India, E-mail: ictrcpune@gmail.com","PeriodicalId":91850,"journal":{"name":"Cancer reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67452643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proof of concept for the clinical utility of a convection enhanced delivery platform for immuno-oncology drugs against brain tumors 针对脑肿瘤的免疫肿瘤药物的对流增强输送平台的临床应用概念证明

Cancer reports and reviews Pub Date : 2019-01-01 DOI: 10.15761/crr.1000197

F. Uckun, S. Qazi, V. Trieu

引用次数: 0

Aberrant expression of p16^INK4a in human cancers - a new biomarker? p16INK4a在人类癌症中的异常表达——一种新的生物标志物?

Cancer reports and reviews Pub Date : 2018-03-01 Epub Date: 2018-01-15 DOI: 10.15761/CRR.1000145

Kazushi Inoue, Elizabeth A Fry

{"title":"Aberrant expression of p16INK4a in human cancers - a new biomarker?","authors":"Kazushi Inoue, Elizabeth A Fry","doi":"10.15761/CRR.1000145","DOIUrl":"https://doi.org/10.15761/CRR.1000145","url":null,"abstract":"The ARF and INK4a genes are located in the same CDKN2a locus, both showing its tumor suppressive activity. ARF has been shown to detect potentially harmful oncogenic signals, making incipient cancer cells undergo senescence or apoptosis. INK4a, on the other hand, responds to signals from aging in a variety of tissues including islets of Langerhans, neuronal cells, and cancer stem cells in general. It also detects oncogenic signals from incipient cancer cells to induce them senescent to prevent neoplastic transformation. Both of these genes are inactivated by gene deletion, promoter methylation, frame shift, and aberrant splicing although mutations changing the amino acid sequences affect only the latter. Recent studies indicated that polycomb gene products EZH2 and BMI1 repressed p16INK4a expression in primary cells, but not in cells deficient for pRB protein function. It was also reported that that p14ARF inhibits the stability of the p16INK4a protein in human cancer cell lines and mouse embryonic fibroblasts through its interaction with regenerating islet-derived protein 3γ. Overexpression of INK4a is associated with better prognosis of cancer when it is associated with human papilloma virus infection. However, it has a worse prognostic value in other tumors since it is an indicator of pRB loss. The p16INK4a tumor suppressive protein can thus be used as a biomarker to detect early stage cancer cells as well as advanced tumor cells with pRB inactivation since it is not expressed in normal cells.","PeriodicalId":91850,"journal":{"name":"Cancer reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018005/pdf/nihms972341.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36265501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30

Aberrant expression of ETS1 and ETS2 proteins in cancer. 癌症组织中ETS1和ETS2蛋白的异常表达。

Cancer reports and reviews Pub Date : 2018-01-01 Epub Date: 2018-04-23 DOI: 10.15761/CRR.1000151

Elizabeth A Fry, Kazushi Inoue

引用次数: 0

The Histogenesis of Ewing Sarcoma. Ewing肉瘤的组织发生。

Cancer reports and reviews Pub Date : 2017-01-01 Epub Date: 2017-02-07 DOI: 10.15761/CRR.1000111

Jian Tu, Zijun Huo, Julian Gingold, Ruiying Zhao, Jingnan Shen, Dung-Fang Lee

引用次数: 18

A rare case: a lung cancer with maxillary metastasis 肺癌合并上颌转移1例

Cancer reports and reviews Pub Date : 1900-01-01 DOI: 10.15761/crr.1000196

A. Gulmez, H Gulbas, M. Ozcan, Elkiran Et

引用次数: 1